Allena Pharmaceuticals, Inc. ROA

ROA of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROA growth rates and interactive chart. Return on Assets (ROA) is an indicator of how well a company utilizes its assets, by determining how profitable a company is relative to its total assets. A company with $1 million in net income and $10 million in average assets will have a 10% ROA.


Highlights and Quick Summary

  • Annual ROA for 2021 was -132.08% (a 46.85% increase from previous year)
  • Annual ROA for 2020 was -89.94% (a -5.63% decrease from previous year)
  • Annual ROA for 2019 was -95.31% (a 115.88% increase from previous year)
  • Twelve month ROA ending March 31, 2022 was -157.03% (a 18.89% increase compared to previous quarter)
  • Twelve month trailing ROA increased by 6.24% year-over-year
Trailing ROA for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-157.03% -132.08% -128.06% -147.8%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROA of Allena Pharmaceuticals, Inc.

Most recent ROAof ALNA including historical data for past 10 years.

Interactive Chart of ROA of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. ROA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -132.08%
2020 -89.94%
2019 -95.31%
2018 -44.15%
2017 -29.79%
2016 -41.02%
2015 -23.85%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.